Funding for this research was provided by:
Ministry of Health, Labour and Welfare (H25-iryogijutsu-ippan-008)
Japan Agency for Medical Research and Development (18lk0201082h0001, 151k0201021h0003)
Received: 7 August 2018
Accepted: 12 October 2018
First Online: 1 November 2018
Ethics approval and consent to participate
: This study is performed in accordance with the Declaration of Helsinki and is approved by the Institutional Review Board of Kobe University Graduate School of Medicine. Before enrollment, patients’ guardians provided written informed consent, and informed assent was obtained from older children.
: Not applicable.
: Mayumi Sako has received a consulting fee from Zenyaku Kogyo Co. Ltd. Koichi Nakanishi has received lecture fees from Novartis Pharma K.K. Kenji Ishikura has received a grant from Chugai Pharmaceutical Co., Ltd. and Pfizer Japan Inc. and a lecture fee from Zenyaku Kogyo Co. Ltd. Kandai Nozu has received lecture fees from Chugai Pharmaceutical Co., Ltd. Kazumoto Iijima has received lecture fees and/or consulting fees from Chugai Pharmaceutical Co., Ltd., Zenyaku Kogyo Co. Ltd., Takeda Pharmaceutical Co., Ltd., Novartis Pharma K.K., Kyowa Hakko Kirin Co. Ltd.MMF is provided by Chugai Pharmaceutical Co., Ltd. The sponsor approved the study protocol, but had no role in data collection, data analysis and drafting or approving the present manuscript.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.